Form D · Other Health Care
Candid Therapeutics, Inc.
San Diego, CA · CIK 0002035778
Offering snapshot reported Sep 13, 2024 · SEC filing
- Reported sold
- $206M Offering amount: $206M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2024 | Initial | $206,203,454 | No comparison | 33 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524038
Total Amount Sold includes amounts paid in both cash and pursuant to conversion of indebtedness.
Source: Form D, filed Sep 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bernie Huyghe, Ph.D. | Executive |
| Arvind Kush | Executive |
| Timothy Lu, M.D. | Executive |
| Michael Rome, M.D. | Director |
| Aaron Royston, M.D. | Director |
| Kenneth Song, M.D. | Director, Executive |
| Jeffrey Tong, Ph.D. | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
11622 El Camino Real, Suite 150
San Diego, CA, 92130
San Diego, CA, 92130